代谢功能障碍相关脂肪肝病提高高肝硬度检出:鹿特丹研究
该研究在鹿特丹研究队列中对5445名参与者进行横断面分析,比较MAFLD与NAFLD标准对肝纤维化(肝硬度≥8.0 kPa)的识别能力。结果显示MAFLD患病率为34.3%,NAFLD为29.5%;仅MAFLD组与纤维化显著相关(调整OR 5.30,p<0.001),而仅NAFLD组无纤维化病例且与肝硬度无关。结论认为采用MAFLD标准有助于识别纤维化风险的脂肪肝患者。
要点
- 仅MAFLD组与纤维化独立相关,调整OR为5.30。
- 仅NAFLD组未发现纤维化病例,与肝硬度无关。
- MAFLD标准或有助于识别纤维化风险的脂肪肝患者。
核心结论
- 仅MAFLD组与纤维化和更高肝硬度相关,且独立于人口学及生活方式因素。
- 采用MAFLD标准有助于改善对纤维化风险脂肪肝患者的识别和治疗。
研究设计与样本
- 基于鹿特丹研究(大型前瞻性人群队列)的横断面分析。
- 纳入2009至2014年参加肝脏超声和瞬时弹性成像程序的参与者,排除病毒性肝炎、酒精摄入>60 g/天、酒精数据缺失和/或BMI缺失者。
- 最终纳入5445名参与者,根据NAFLD和MAFLD标准分为重叠FLD、仅NAFLD、仅MAFLD和无FLD四组。
- 纤维化定义为肝硬度≥8.0 kPa。
主要发现
- 5445名参与者中,MAFLD患病率为34.3%(1866人),NAFLD患病率为29.5%(1604人)。
- 分组结果:重叠FLD 1547人(28.4%),仅MAFLD 319人(5.9%),仅NAFLD 57人(1.0%),无FLD 3522人(64.7%)。
- 仅MAFLD组与纤维化强烈相关(调整OR 5.30,p<0.001),并与对数转换肝硬度相关(调整beta 0.116,p<0.001)。
- 仅NAFLD组未发现纤维化病例,且与肝硬度无关联(调整beta 0.006,p=0.90)。
关键数值与推荐
- MAFLD定义为肝脂肪变合并超重、糖尿病和/或其他代谢危险因素的组合。
- 纤维化判定标准为肝硬度≥8.0 kPa。
- 排除标准包括病毒性肝炎、酒精摄入>60 g/天、酒精数据缺失和/或BMI缺失。
临床怎么用
- 在脂肪肝患者评估中,采用MAFLD标准可能比NAFLD标准更有效地识别纤维化高风险个体。
- 对于符合MAFLD但不符合NAFLD的患者,应关注肝硬度检测以评估纤维化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recently metabolic dysfunction-associated fatty liver disease (MAFLD) has been introduced and was defined as hepatic steatosis with either overweight, diabetes, and/or a combination of other metabolic risk factors. We investigated the application of the MAFLD criteria as compared with NAFLD. APPROACH AND RESULTS: We performed a cross-sectional analysis within the Rotterdam Study, a large prospective population-based cohort. Participants who attended the liver ultrasound and transient elastography program between 2009 and 2014 were eligible for inclusion. Subsequently, individuals with viral hepatitis, alcohol intake >60 g/day, missing alcohol data, and/or missing body mass index were excluded. According to their NAFLD and MAFLD status based on metadata and ultrasound, participants were allocated in overlap fatty liver disease (FLD), NAFLD-only, MAFLD-only, or no FLD. Fibrosis was defined as liver stiffness ≥8.0 kPa. In our analysis, 5445 participants were included: 1866 (34.3%) had MAFLD and 1604 (29.5%) [Correction added on December 27, 2021 after first online publication: The preceding fragment was changed from "1623 (29.8%)"] had NAFLD. This resulted in 1547 (28.4%) [Correction added on December 27, 2021 after first online publication: The preceding fragment was changed from "1566 (28.8%)"] individuals with overlap FLD, 319 (5.9%) [Correction added on December 27, 2021 after first online publication: The preceding fragment was changed from "300 (5.5%)"] with MAFLD-only, 57 (1.0%) with NAFLD-only, and 3522 (64.7%) with no FLD. The MAFLD-only group was strongly associated with fibrosis (adjusted OR 5.30 [Correction added on December 27, 2021 after first online publication: The preceding fragment was changed from "OR 5.27"], p < 0.001) and log-transformed liver stiffness (adjusted beta 0.116, p < 0.001), as opposed to the NAFLD-only group, in which no cases of fibrosis were identified and no association with liver stiffness (adjusted beta 0.006, p = 0.90) was found. CONCLUSIONS: FLD is highly prevalent in the general population. However, not the NAFLD-only, but the MAFLD-only group was associated with fibrosis and higher liver stiffness-independent of demographic and lifestyle factors. We believe that using the MAFLD criteria will help improve the identification and treatment of patients with FLD at risk for fibrosis.
引用
- van Kleef LA, Ayada I, Alferink LJM, et al. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology. 2021. PMID: 34453359. doi:10.1002/hep.32131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。